Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
BMJ Open|July 22, 2020
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocolAlberto Bongiovanni, Chiara Liverani, Sara Pusceddu, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|October 29, 2009
PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary casesAngela Michelucci, Claudio Di Cristofano, Azzurra Lami, et al.
Journal of Hepatology|January 17, 2012
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalysesJean-Luc Raoul, Jordi Bruix, Tim F Greten, et al.
Cancer Investigation|April 25, 2007
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patientsPaolo Carlini, Andrea Michelotti, Gianluigi Ferretti, et al.
Cancer|October 21, 2006
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III StudyEmilio Bajetta, Giuseppe Procopio, Laura Catena, et al.
Neuroendocrinology|January 21, 2016
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological FactorsFrancesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, et al.
Cancer Biomarkers : Section a of Disease Markers|December 28, 2017
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomasIacopo Petrini, Monica Lencioni, Enrico Vasile, et al.
Radiation Oncology (London, England)|January 23, 2016
[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary resultsFrancesco Pasqualetti, Marco Panichi, Aldo Sainato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord OvestAlfredo Falcone, Sergio Ricci, Isa Brunetti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2019
[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancerFrancesco Pasqualetti, Marco Panichi, Martina Sollini, et al.
Pageof 5